Sotyktu™ (deucravacitinib) – New drug approval
September 9, 2022 - Bristol Myers Squibb announced the FDA approval of Sotyktu (deucravacitinib), for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Download PDF
